Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Dr. Reddy's Laboratories Ltd. (RDY - Snapshot Report) recently announced the launch of Zenatane (isotretinoin) capsules, its generic version of Hoffman-La Roche Inc.’s acne drug Accutane. The launch followed the approval by the US Food and Drug Administration (FDA) of the company’s Abbreviated New Drug Application (ANDA) for Zenatane.

The US regulatory body gave its approval for the 10 mg, 20 mg and 40 mg dosage strengths of the drug. Dr. Reddy’s has not yet launched the 10 mg version.

According to IMS Health, generic Accutane generated US revenues of approximately $309 million for the 12 months ending Jan 2013.

We remind investors that in Jun 2009, Hoffman-La Roche Inc. had notified the FDA about its intention to discontinue Accutane in the US due to the presence of generic competitors like Mylan Pharmaceuticals Inc. (MYL - Analyst Report) and Ranbaxy Laboratories Inc.

Dr. Reddy's boasts of a strong generic product portfolio. The company’s Global Generics segment revenues jumped 25% year over year to $380 million in the third quarter of fiscal 2013 (ended Dec 31, 2012). Strong sales in North America and the emerging market territories were primarily responsible for the growth displayed by the Global Generics division.

Generics revenue increased in North America (up 38%), Russia and other CIS (Commonwealth of Independent States) markets (up 32%), India (up 12%) and the rest of the world/RoW (up 42%).  However, generic revenues declined 20% in Europe.

Dr. Reddy’s also has a robust generic pipeline. In Mar 2013, Dr. Reddy's launched its bioequivalent generic version of Novartis AG’s (NVS - Snapshot Report) Zometa (zoledronic acid 4 mg/5 mL) injection in the US. Zometa is indicated for the treatment for hypercalcemia of malignancy.

The stock carries a Zacks Rank #3 (Hold). Another generic player, Akorn, Inc. (AKRX - Snapshot Report), looks more promising and carriesa Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%